Sero-Prevalence of Antibodies against Varicella Zoster Virus in Children under Seven-Years Old in 2012 in Tehran, Iran

Yasaman VOJGANI 1,2, Saeed ZAREI 1, Samira RAJAEI 3, Leili CHAMANI-TABRIZ 4, Fatemeh GHAEMIMANESH 1, Nematallah MOHAMMADINIA 5, *Mahmood JEDDI-TEHRANI 1

1. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
2. Islamic Azad University, Science and Research Branch, Arak, Iran
3. Lab Sciences Department, School of Allied Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
4. Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR
5. East Health Center, Shahid Beheshti University of Medical Science, Tehran, Iran

*Corresponding Author: Tel: +982122432020, Email: mahjed@yahoo.com
(Received 20 Apr 2014; accepted 13 July 2014)

Abstract

Background: Varicella zoster virus (VZV) is a member of herpes family viruses, which causes varicella (chickenpox) after primary infection and herpes zoster (shingles) because of latent virus reactivation from dorsal root ganglia. Generally, prevalence of varicella antibodies increases with age. We aimed to compare the prevalence of anti-VZV antibody in children under seven years old, in order to obtain a preliminarily picture of general presence of these antibodies to design an immunization plan.

Methods: In this cross-sectional study, performed from September 2011 to September 2012 in Tehran, Iran, 267 serum samples including sera from 7 month old infants, n= 87; 18 month old children, n= 86; and 6 year old children, n= 94 were assessed for the presence of specific IgG antibodies against VZV, using ELISA technique.

Results: 4.6% of 7 month, 12.8% of 18 month and 21.3% of 6-year-old children were seropositive. No relation was found between demographic variables (e.g. age and birth weight) and seropositivity in these age groups. VZV antibodies increased with age. Serum levels of varicella antibodies were elevated in 18 months old compared to 7 months old children, significantly (P < 0.001).

Conclusion: In view of the significant elevation of VZV antibodies in children from 7 months to 18 months of age and rate of seronegative children, our results support the necessity of varicella immunization between 7 and 18 months of age in order to prevent viral infection.

Keywords: Antibody, Children, Prevalence, Varicella-zoster virus

Introduction

Primary infection with varicella zoster virus (VZV) which is a mild to moderate self-limited disease causes varicella (chickenpox) in children (1). Because of the waning VZV specific cell mediated immunity, virus reactivation in relation to suppressed immune conditions or elder people, could induce herpes zoster (2, 3). Varicella zoster is accompanied by serious complications such as post-herpetic neuralgia, viral pneumonia and encephalitis (4, 5). Herpes zoster frequency and its most common complications are likely to increase with age (6). The virus is usually transmitted 1-2 days before appearance of rashes via respiratory droplets, vesicle fluid, direct contact or aerosol
exposure to the vesicular lesions of a patient with varicella. Also, in hospital setting, airborne transmission has been described (7, 8).

Following VZV exposure (primary infection or vaccination), VZV antibodies appear in serum. Different studies have confirmed the increasing trend in VZV seroprevalence parallel to aging (9, 10). One survey that was conducted before VZV mass vaccination during 1988-1994, demonstrated a high VZV seroprevalence ranging from 86% in 6-11 years old children to 99% in ≥30 years old individuals(6). Another study reported that 49% of 2 years old and 93% of 5 years old children were VZV seropositive before VZV vaccination (11). VZV seroprevalence is diverse in different studies depending on race, gender, country and number of siblings in a household (6, 12, 13).

A highly efficient strategy to eliminate VZV infection and its related complications is the routine varicella vaccination (14). Since 1974 a live-attenuated varicella vaccine has been proven safe and effective and universal childhood immunization has been implemented in several countries(15). It is well documented universal vaccination of children would increase the prevalence of VZV protective antibodies in the population (16, 17). A number of studies on the prevalence of antibodies against this virus have been conducted in different countries (18-20). In France, general vaccination against varicella zoster indicated at least 80% efficacy in reduction of VZV infection (21). Besides, a survey in Brazil in 2006 reported that varicella immunization developed 70-90% protection against any form of varicella zoster infection (22). Although varicella immunization schedule has been well established in health care systems of many countries (23, 24), immunization against this virus, has not been included in official vaccination program in Iran.

The present study aimed to compare the prevalence of anti-VZV antibody in three groups of children under 7 years old in Tehran, Iran, in order to obtain an informative picture of general presence of these antibodies for designing a comprehensive immunization plan.

Material and Methods

Study population
This cross-sectional study was conducted between October 2011 and July 2012 at Avicenna Research Institute, Tehran, Iran. The study population included 7 months, 18 months and 6-year-old healthy children who attended to health care centers for routine vaccinations. These health care centers provide general vaccination services to children and adults with different socio-demographic status representative of an ordinary population. Written informed consents were obtained from the parents of children after declaring the process of the study. The parents completed the questionnaires containing general information such as age, birth weight, and previous history of VZV infections in children.

The subjects were categorized in three age groups consisting of 7 month, 18 month and 6-year-old children. It is important to note that the 7 months old children were bled again at the age of 18 months; Thus, the corresponding 7 and 18 months old children blood samples were taken from the same individuals.

An approval for the study was obtained from the local Ethical Committee.

Serological assessments
Two and a half milliliters of venous blood sample were taken from each person. Serum samples were separated and stored at -20 °C until used. Serological tests were conducted by ELISA kit (Euroimmune anti-varicella-zoster virus IgG ELLISA medizinische labor diagnostka AG, Lubeck, Germany). Serum antibody levels were defined according to the manufacturer’s instructions as follows: <80 IU/L: Negative, 80-110 IU/L: Borderline and >110 IU/L: positive. The test was defined to have a specificity of 100% and a sensitivity of 100%, according to the manufactures instructions.

Statistical analyses
Statistical analyses were performed using statistical package for the social sciences SPSS version 13.0
(SPSS Inc, Chicago, IL, USA). The prevalence rates of VZV antibodies were calculated for the different age groups. Differences in antibody titers for the different age groups were assessed using chi-square, independent t-test and Paired T-test. Gender and age were included in the multi-variant logistic regression analyses. P-values < 0.05 were considered statistically significant.

Results

Participants' characteristics

In this study totally 86 boys and 95 girls were included. 267 serum samples were collected from September 2011 to September 2012. From these specimens, 87 were taken from 7 month old infants, 86 of whom come back again for sampling at the age of 18 months and 94 serum samples belonged to 6 year old children. According to the filled questionnaires, none of the parents reported past history of VZV infection in their children. Mean birth weights and visited-day weights of subjects in different age groups were 3.2 ± 0.3 kg, and 5.0 ± 0.9 kg (7 months), 3.2 ± 0.3 kg and 11.0 ± 1.1 kg (18 months) and 3.2 ± 0.4 kg and 20.3 ± 2.7 kg (6 years), respectively. No significant difference was found between birth weights and visited-day weights with gender (P > 0.05) (Table1).

Table 1: Birth weights and visited- day weights in different age groups of Iranian children

| Age      | Gender | Birth weight Mean± SD (kg) | Visited-day weight Mean± SD (kg) | P-valued* (birth weight) | P-value * (visited-day weight) |
|----------|--------|-----------------------------|---------------------------------|--------------------------|--------------------------------|
| 7 months | Male   | 3.03 ± 0.4                  | 4.9 ± 0.7                       | 0.158                    | 0.592                          |
|          | Female | 3.1 ± 0.3                   | 4.8 ± 0.6                       |                          |                                |
| 18 months| Male   | 3.3 ± 0.4                   | 11.1 ± 0.7                      | 0.158                    | 0.638                          |
|          | Female | 3.1 ± 0.3                   | 11.0 ± 1.2                      |                          |                                |
| 6 years  | Male   | 3.3 ± 0.3                   | 20.3 ± 2.0                      | 0.746                    | 0.576                          |
|          | Female | 3.2 ± 0.4                   | 20.7 ± 2.3                      |                          |                                |

*Evaluated by independent t-test

Seroprevalence of anti-VZV in the study population

The Mean antibody concentrations against VZV were 183 ± 781 IU/L, 327 ± 878 IU/L and 425 ± 107 IU/L in 7 months, 18 months and 6 years old subjects, respectively. The seropositive rates were 4.6%, 12.8% and 21.3% for 7 month, 18 month and 6-year-old individuals, respectively. Table 2 shows antibody titers against VZV and seropositive rates of subjects in each age group and their distribution according to the gender. Our findings showed no significant difference in anti-VZV antibody concentrations and seropositive rates related to gender in each of age groups (P > 0.05) (Table2). This study also demonstrated the increasing trend of prevalence of seropositivity (Fig. 1).

Fig. 1: VZV antibody prevalence was shown in three age groups. Positive seroprevalence rates were increased along with age increasing (difference was not statistically significant)
Comparison of antibody titers against VZV in 6 year old children with that in 7 months age ($P=0.086$) and 18 months age ($P=0.506$) groups showed no significant differences, but the rates of seropositive subjects were significantly higher in 6 year old children compared to 7 months old infants ($P = 0.001$, chi-square). Anti-VZV antibody titers increased significantly by age when they were measured in the same individuals at 7 months and 18 months of age ($P< 0.001$, Paired $t$-test). Multiple linear regression did not show any significant correlation between demographic characters (gender, birth weight, visited-day weight) and anti-VZV antibody titers in different age groups (Table 3).

**Table 2:** Mean antibody titers against VZV and seropositive rates in different age groups of Iranian children

| Age     | Gender | No. of subjects | Anti-VZV (IU/L) Mean ± SD | Seropositive > 110 IU/L n (confidence interval of 95% for prevalence) | $P$- value* (Anti- VZV relative to gender) | $P$- Value** (seropositive relative to gender) |
|---------|--------|-----------------|---------------------------|---------------------------------------------------------------------|-------------------------------------------|-----------------------------------------------|
| 7 months| Male   | 39              | 125 ± 678                 | 1 (0.03-0.8)                                                         | 0.540                                     | 0.390                                         |
|         | Female | 48              | 229 ± 860                 | 3 (0.01-0.13)                                                       |                                           |                                               |
|         | All    | 87              | 183±781                   | 4 (0.00-0.09)                                                       |                                           |                                               |
| 18 months| Male  | 38              | 380 ± 933                 | 6 (0.04-0.28)                                                       | 0.623                                     | 0.337                                         |
|         | Female | 48              | 286 ± 840                 | 5 (0.01-0.19)                                                       |                                           |                                               |
|         | All    | 86              | 327±878                   | 11 (0.06-0.20)                                                      |                                           |                                               |
| 6 years | Male   | 47              | 430 ± 1109                | 10 (0.09-0.33)                                                      | 0.969                                     | 0.599                                         |
|         | Female | 47              | 421 ± 1047                | 10 (0.09-0.33)                                                      |                                           |                                               |
|         | All    | 94              | 425±107                   | 20 (0.13-0.30)                                                      |                                           |                                               |

*Evaluated by independent $t$- test/** Evaluated by Chi-square

**Table 3:** Multiple linear regressions between demographic characters (gender, birth weight, visited- day weight) and anti-VZV antibody titers in different age groups of Iranian children. Values show $P$-values of multiple linear regression

| Age     | variables | B      | Beta  | p-value |
|---------|-----------|--------|-------|---------|
| 7 months| Gender    | -120.898| -.126 | .281 |
|         | Birth weigh | .047 | .033 | .790 |
|         | Visited-day weight | -.042 | -.079 | .532 |
| 18 months| Gender    | 60.962 | .035 | .768 |
|         | Birth weigh | .244 | .096 | .423 |
|         | Visited-day weight | .060 | .079 | .512 |
| 6 years | Gender    | 92.612 | .039 | .748 |
|         | Birth weigh | .065 | .022 | .858 |
|         | Visited-day weight | .111 | .252 | .051 |

**Discussion**

This study was conducted to generate data on the epidemiology of VZV infection in a limited population of Iranian children with the aim to establish a preliminary report as a basis for larger studies for health system improvement in varicella vaccination strategies.

Protection against VZV in neonates is dependent on maternal immunity until they are 6 months old when the production of antibody by their own immune systems begins (19, 25). Since we did not have access to confirmed history of immunity in mothers, we selected 7 months old infants to determine their seroprevalence of anti-VZV antibodies. Our results regarding similar anti-VZV prevalence rates in different genders are confirmed by previous reports (10, 26-28). The age group specific prevalence in our survey suggests that the seropositivity of antibodies against VZV increases with age. The prevalence of VZV antibodies were 7.1% , 5.6% and 18.2% in 9 , 15 and
24 months old subjects, respectively (10). Also, 16% of 1 year old children and 25.1% of children between 2-3 years old were seropositive in a cross-sectional study in Cyprus (9). In Thailand, seropositivity rate increased from 15.5% in children (between 9 months and 4 years old), to 75.9% in adults (20-29 years old) (29). Thiry et al. reported 29-35% seropositivity in 1-year-old, 80.19% in 5 year old and 84.78% in 6-year-old individuals in Flanders (30). Similarly, in Italy, seroprevalences of varicella were reported to be 32.9%, 67% and 84% in the age classes: 2-4, 5-9 and 10-14 years, respectively (31). It could be noticeably deduced that the increasing trend in prevalence of anti-VZV antibodies with age is evident (27), however the prevalence rates may be different from our results (32, 33). The elevated levels of prevalence in these countries may be related to increased exposure to virus after natural infection, since all these studies were conducted before their vaccination plans started. The elevation in VZV antibody titers following vaccination causes diminishing impact on incidence of chickenpox and zoster infection. Findings of a survey demonstrated varicella vaccination could induce 34.7% decrease in the incidence of varicella among 0-14 year old children and 51% reduction in the number of complications associated to varicella (3, 34). In addition, another study reported of 55% reduction in varicella cases in the studied population that included 63% and 38% reduction in 0-4 and 5-9 years old children, respectively (35). Similar results were also reported in other studies (36, 37). Besides, in France, seropositivity was reported in 15% of 1-2 year and 89% of 7-8 year old children (20). In a similar trend, in Malaysia 25.6% of 1-5, 47.2% of 6-10 and 50.8% of 11-15 old children were reported as seropositive (38). This increasing pattern was also observed in India, Canada and other countries (18, 31, 39-42). The unique characteristic of our study has been the provision of an opportunity to investigate the association between antibody titers within a person at different ages that revealed a significant increase by age. Protective role of maternal antibody against VZV is durable up to 6 months (19). With the advent of VZV vaccine, the incidence of VZV infection in children and adults has decreased and the breakthroughs are minimizing. This vaccine is not routinely used in Iran, however this important subject was considered from 1988 to 1995 in Japan, Turky and The United States. In The USA, the combination of MMR and Varicella Zoster Vaccine (MMRV) was allowed for children between 12 months and 12 years of age in 2005 (42, 43).

According to our results, we suggest usage of MMRV vaccine to be administered in children.

**Conclusion**

Our findings that, significant elevation of VZV antibodies occur from 7 to 18 months of age and rate of seronegative children support the necessity of varicella immunization at this age range in order to prevent virus infection. Since serious complications and long-lasting sequels have been reported after VZV infection, it may be recommended that VZV vaccination be integrated in the Iran national vaccination program. In this regard, larger and more comprehensive studies need to be conducted to warrant information required for decision-making.

**Ethical considerations**

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

**Acknowledgements**

The authors are grateful to the parents who accepted to allow their children to enter in the study. We are indebted to the personnel of Mohammadian, Dawazdah Bahman, Saffar and Salavati Health Centers of Shahid Beheshti University of Medical Science for their assistance in sample collection. This work was supported by a grant (91-004) from Avicenna Research Institute. The authors declare that there is no conflict of interests.

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
References

1. Aebi C, Fischer K, Gorgievski M, Matter LM, Muhleman K (2001). Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. *Vaccine*, 19:3097-103.

2. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ (2002). Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. *Vaccine*, 20:2500-7.

3. Chuang YY, Huang YC, Chang LY, Chiu CH, Lin TY (2003). Complications of varicella requiring hospitalisation before and after the introduction of varicella vaccine in a children's hospital in Taiwan. *Eur J Pediatr*, 162:112-3.

4. Chan JY, Tian L, Kwan Y, Chan W, Leung C (2011). Hospitalizations for varicella in children and adolescents in a referral hospital in Hong Kong, 2004 to 2008: a time series study. *BMC Public Health*, 11:366.

5. Uebe B, Sauerbrei A, Burdach S, Horn effortlessly G (2002). Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. *Eur J Pediatr*, 161:442-4.

6. Kilgore PE, Kriszton-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, McQuillan GM, Wharton M, Fehr LI, Cossen CK, Hadler SC (2003). Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol*, 70 Suppl 1:S111-8.

7. Holmes CN (2005). Predictive value of a history of varicella infection. *Can Fam Physician*, 51:60-5.

8. Wu MF, Yang YW, Lin WY, Chang CY, Soon MS, Liu CE (2012). Varicella zoster virus infection among healthcare workers in Taiwan: seroprevalence and predictive value of history of varicella infection. *J Hosp Infect*, 80:162-7.

9. Kurugol Z, Koturoglu G, Aksit S, Ozacar T (2007). Varicella seroprevalence in Turkish population in Cyprus. *Acta Paediatr*, 96:861-3.

10. Ozkan S, Maral I, Ilhan F, Aycan S, Cirak MY, Beyazova U, Aygun R (2005). Varicella zoster seroprevalence in children less than 5 years old. *J Trip Pediatr*, 51:141-4.

11. de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, de Wit A, Boot H (2006). The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. *Vaccine*, 24:3946-52.

12. Gershon AA, Raker R, Steinberg S, Topf-Olstein B, Drusin LM (1976). Antibody to Varicella-Zoster virus in parturient women and their offspring during the first year of life. *Pediatrics*, 58:692-6.

13. Heining U, Braun-Fahrlander C, Desgrandchamps D, Glaas J, Grize L, Wutzler P, Schaad UB (2001). Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity. *Pediatr Infect Dis J*, 20:775-8.

14. Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P (1996). The protective effect of immunologic boosting against zoster: an analysis in leukemia children who were vaccinated against chickenpox. *J Infect Dis*, 173:450-3.

15. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, Coplan P, Sharrar R, Guess H (1999). Postmarketing evaluation of the safety and effectiveness of varicella vaccine. *Pediatr Infect Dis J*, 18:1041-6.

16. Gershon AA (1992). Varicella vaccine: still at the crossroads. *Pediatrics*, 90:144-8.

17. Salleras L, Dominguez A, Vidal J, Plans P, Salleras M, Taberner JL, Pablos-Mendez A (2000). Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. *Vaccine*, 19:183-8.

18. Cohen DI, Davidovicci BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS (2006). Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines. *Infection*, 34:208-13.

19. Heining U, Desgrandchamps D, Schaad UB (2006). Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age. *Vaccine*, 24:3258-60.

20. Khoshnood B, Debruyne M, Lancon F, Emery C, Fagnani F, Durand I, Floret D (2006). Seroprevalence of varicella in the French population. *Pediatr Infect Dis J*, 25:41-4.

21. Bonmarin I, Santa-Olalla P, Levy-Bruhl D (2008). [Modelling the impact of vaccination on the epidemiology of varicella zoster virus]. *Rev Epidemiol Sante Publique*, 56:323-31.

22. Bricks LF, Sato HK, Osella GW (2006). Varicella vaccines and measles, mumps, rubella, and varicella vaccine. *J Pediatr (Rio J)*, 82:8101-8.
23. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G (2000). Modelling the impact of immunization on the epidemiology of varicella zoster virus. *Epidemiol Infect*, 125:651-69.

24. Gao Z, Gidding HF, Wood JG, MacIntyre CR (2010). Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. *Epidemiol Infect*, 138:457-68.

25. Saha SK, Darmstadt GL, Hanif M, Khan R (2002). Seroepidemiology of varicella-zoster virus in Bangladesh. *Am Trop Paediatr*, 22:341-5.

26. O'Grady KA, Merianos A, Patel M, Gilbert L (2000). High seroprevalence of antibodies to varicella zoster virus in adult women in a tropical climate. *Trop Med Int Health*, 5:732-6.

27. Semenovitch I, Lupi O (2003). A seroepidemiologic survey of the prevalence of varicella-zoster virus in the pediatric population in two university hospitals in Brazil. *Int J Dermatol*, 42:193-6.

28. Sharifi Z, Emadi Ghanjin S (2005). The Seroepidemiology of Varicella Zoster Virus (VZV) in Different Age Groups in Tehran, Iran. *Iran J Allergy Asthma Immunol*, 4:95-8.

29. Lolekha S, Sornchai P, Kosuwan P, Sutra S, Warachit B, Chup-Upprakarn S, Hutagalang Y, Weil J, Bock HL (2001). Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. *Am J Trop Med Hyg*, 64:131-6.

30. Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV, Damme PV (2002). The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). *Eur J Pediatr*, 161:588-93.

31. Gabutti G, Rota MC, Guido M, De Donno A, Bella A, Ciofi degli Atti ML, Crovari P (2008). The epidemiology of Varicella Zoster Virus infection in Italy. *BMC Public Health*, 8:372.

32. Carville KS, Riddell MA, Kelly HA (2010). decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. *Vaccine*, 28:2532-8.

33. van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay (2011). N Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. *Vaccine*, 29:2411-20.

34. Baldo V, Baldovin T, Russo F, Busana MC, Piovesan C, Bordignon G, Giliberti A, Trivello R (2009). Varicella: epidemiological aspects and vaccination coverage in the Veneto Region. *BMC Infect Dis*, 9:150.

35. Siedler A, Arm D (2010). Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. *Eur Surveill*, 15.

36. Katasfadou A, Kallergi K, Ferentinos G, Goulioti T, Foustoukou M, Papaevangelou V (2009). Presumptive varicella vaccination is warranted in Greek adolescents lacking a history of disease or household exposure. *Eur J Pediatr*, 168:23-5.

37. Suo LD, Lu L, Wu J, Liu DL, Pang XH (2012). [The epidemiological impact of varicella vaccination in kindergartens, primary and secondary schools in Beijing]. *Zhonghua Yu Fang Yi Xue Za Zhi*, 46:46-9.

38. Lee BW (1998). Review of varicella zoster seroepidemiology in India and Southeast Asia. *Trop Med Int Health*, 3:886-90.

39. Ratnam S (2000). Varicella susceptibility in a Canadian population. *Can J Infect Dis*, 11:249-53.

40. Kanra G, Tezcan S, Badur S (2002). Varicella seroprevalence in a random sample of the Turkish population. *Vaccine*, 20:1425-8.

41. Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A (2001). Seroprevalence of varicella-zoster virus in the German population. *Vaccine*, 20:1245-8.

42. Kim YH, Hwang JY, Lee KM, Choi JH, Lee TY, Choi J, Park HS (2011). Seroepidemiologic survey of varicella-zoster virus in korean adults using glycoprotein enzyme immuno assay and fluorescent antibody to membrane antigen test. *Ann Dermatol*, 23:39-43.

43. Oliveira J, Dias N, Ferreira TM, da Cunha S, Costa D, Corte-Real R, Melico-Silvestre A (1999). [The determination of susceptibility to measles, rubella, mumps and chickenpox in students of health-related areas]. *Acta Med Port*, 12:155-60.

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)